Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, today announced positive safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data from its phase 1 studies of CYB004 (“IV” administration) and SPL028 (“IV” and “IM” administration) in healthy volunteers. CYB004 and SPL028 … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Topline Data from Phase 1 CYB004 and SPL028 Studies